• Portrait
  • Career

Dieter Gericke heads the Corporate / M&A practice team. He focuses on public and private M&A, shareholder activism, equity capital markets (incl. IPOs), private equity and corporate governance. He advises in matters of corporate law as well as securities regulations.

Dieter Gericke heads the Corporate / M&A practice team. He focuses on public and private M&A, shareholder activism, equity capital markets (incl. IPOs), private equity and corporate governance. He advises in matters of corporate law as well as securities regulations.

2014
Head of the Corporate / M&A practice team
2010
Head of the China Focus Group
2004
Partner at Homburger
1999
Foreign Associate at Wilmer Hale, Boston
1999
Harvard Law School (LL.M.)
1996
University of Zurich (Dr. iur.)
1994
Bar admission / Research assistant at the University of Zurich
1991
Law clerk at the District Court of Meilen-Zurich
1991
University of Zurich (lic. iur.)

Dieter Gericke advises on transactions within the life sciences field, as well as providing expertise in capital increases. One client underlines his ‹business-oriented› approach.

2020

Dieter Gericke is popular with clients from the financial and pharmaceutical industries. Gericke represents clients in both sales and acquisitions, and sources particularly highlight his approach in transactions, saying: ‹He is good at being commercial and pragmatic›.

2020

Dieter Gericke is singled out by peers in the Swiss market as a go-to practitioner for IPO and financing matters.

2020

Dieter Gericke comes highly recommended by market commentators who compliment his ‹great capacity for analysis› adding, ‹He is always available, very analytical and has a lot of experience›.

2020

  • Bulletin
  • News
  • Publications

Homburger advised Molecular Partners in connection with a collaboration with Novartis to develop DARPin® therapies designed for potential use against COVID-19

Deals & Cases

Homburger advises Credit Suisse on the envisaged merger with Neue Aargauer Bank

Deals & Cases

Homburger advises ADC Therapeutics SA in its follow-on public offering in the United States

Deals & Cases

Good Corporate Governance: Von der Zielsetzung zur Unternehmensorganisation – am Beispiel des neuen Aktienrechts

Dieter GerickeMichael Lüchinger

Nachfolgeplanung im Lichte von Aktivismus, Nachhaltigkeit, Diversity und Corona-Krise

Join the Team

Career

Dieter Gericke

Partner

Dieter Gericke heads the Corporate / M&A practice team. He focuses on public and private M&A, shareholder activism, equity capital markets (incl. IPOs), private equity and corporate governance. He advises in matters of corporate law as well as securities regulations.

Among other matters Dieter Gericke’s assignments included advising ChemChina in the public takeover of Syngenta, EF in the sale of its China kids business, Therachon in the sale to Pfizer, Meyer Burger in a proxy fight and capital increase, Bregal in the acquisition of Kunststoff Schwanden, Bühler in the acquisition of Haas Group, Givaudan in the acquisition of Induchem, Infront Sports & Media in the sale to Dalian Wanda, Nestlé in the sale of Alcon to Novartis, Kering in the acquisition of Ulysse Nardin or SCOR in the unsolicited takeover of Converium. He advised on numerous IPOs, including ADC Therapeutics, Zur Rose Group, AC Immune, Endosense, Kuros Biosurgery, Molecular Partners, Gategroup, Santhera, BioXell or tamedia. He has long-standing experience in assisting boards of directors and managements of public and private companies in corporate governance matters and specific challenges like shareholder activism and -claims, proxy-fights, securities regulations, reorganizations and directors’ & officers’ liability. Dieter Gericke has a particularly strong foothold in the life sciences, chemicals, engineering and technology as well as insurance industries.

Dieter Gericke is a member of the Corporate and M&A Committee and the Securities Law Committee of the International Bar Association.
Dieter Gericke has chaired or been a speaker at numerous conferences with recent speaking topics including M&A. shareholder activism, proxy advisors, private equity, negotiation tactics, takeover laws or joint ventures.

In his areas of practice Dieter Gericke authored various publications and legal opinions, including on mergers & acquisitions, securities laws, directors’ and officers’ duties and liability and corporate governance.Dieter Gericke joined Homburger as an associate in 2000 and has been partner since 2004 and head of the Corporate M&A practice team since 2014. Since 2010, he also heads the Homburger China Group. He studied law at the University of Zurich, where he graduated and accomplished his doctorate, both summa cum laude. In 1999, he graduated from Harvard Law School with an LL.M. In addition, Dieter Gericke studied one semester at Université de Paris II (Assas).

Dieter Gericke has been a member of the boards of directors of Syngenta AG and, since many years, of Gericke Group, which produces powder processing equipment and systems for food, pharma and chemical industries. In addition he is serving in honorary capacity as a member of the board of supervisors of Theater an der Winkelwiese, Zurich and of the Harvard Club of Switzerland.

Career

2014
Head of the Corporate / M&A practice team
2010
Head of the China Focus Group
2004
Partner at Homburger
2000
Associate at Homburger
1999
Foreign Associate at Wilmer Hale, Boston
1999
Harvard Law School (LL.M.)
1996
Associate at a Zurich law firm
1996
Lecturer in Corporate Law at the University of Zurich
1996
University of Zurich (Dr. iur., summa cum laude)
1994
Bar admission / Research assistant at the University of Zurich
1991
Law clerk at the District Court of Meilen-Zurich
1991
University of Zurich (lic. iur., summa cum laude)

Languages

French, English, German

Bar Registration

Admitted to the Swiss bar

Teams